We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Department of Anesthesiology
1980
Yao FS, Seidman SF, Artusio JF.  1980.  Disturbance of consciousness and hypocalcemia after neomycin irrigation, and reversal by calcium and physostigmine.. Anesthesiology. 53(1):69-71.
Donlon JV, Savarese JJ, Ali HH, Teplik RS.  1980.  Human dose-response curves for neuromuscular blocking drugs: a comparison of two methods of construction and analysis.. Anesthesiology. 53(2):161-6.
Martyn JA, Szyfelbein SK, Ali HH, Matteo RS, Savarese JJ.  1980.  Increased d-tubocurarine requirement following major thermal injury.. Anesthesiology. 52(4):352-5.
Lebowitz PW, Ramsey FM, Savarese JJ, Ali HH.  1980.  Potentiation of neuromuscular blockade in man produced by combinations of pancuronium and metocurine or pancuronium and d-tubocurarine.. Anesth Analg. 59(8):604-9.
Ali HH, Savarese JJ.  1980.  Stimulus frequency and dose-respone curve to d-tubocurarine in man.. Anesthesiology. 52(1):36-9.
1981
Lebowitz PW, Ramsey FM, Savarese JJ, Ali HH, deBros FM.  1981.  Combination of pancuronium and metocurine: neuromuscular and hemodynamic advantages over pancuronium alone.. Anesth Analg. 60(1):12-7.
Friedberg SJ, Gomillion M.  1981.  Hydrogen exchange in the formation of dihydroxyacetone phosphate from acyl dihydroxyacetone phosphate in O-alkyl lipid synthesis in Ehrlich ascites tumor cell microsomes.. J Biol Chem. 256(1):291-5.
Savarese JJ.  1981.  The new neuromuscular blocking drugs are here.. Anesthesiology. 55(1):1-3.
Moss J, Rosow CE, Savarese JJ, Philbin DM, Kniffen KJ.  1981.  Role of histamine in the hypotensive action of d-tubocurarine in humans.. Anesthesiology. 55(1):19-25.
Ali HH, Savarese JJ, Lebowitz PW, Ramsey FM.  1981.  Twitch, tetanus and train-of-four as indices of recovery from nondepolarizing neuromuscular blockade.. Anesthesiology. 54(4):294-7.
Philbin DM, Moss J, Akins CW, Rosow CE, Kono K, Schneider RC, VerLee TR, Savarese JJ.  1981.  The use of H1 and H2 histamine antagonists with morphine anesthesia: a double-blind study.. Anesthesiology. 55(3):292-6.
1982
Basta SJ, Ali HH, Savarese JJ, Sunder N, Gionfriddo M, Cloutier G, Lineberry C, Cato AE.  1982.  Clinical pharmacology of atracurium besylate (BW 33A): a new non-depolarizing muscle relaxant.. Anesth Analg. 61(9):723-9.
Moss J, Philbin DM, Rosow CE, Basta SJ, Gelb C, Savarese JJ.  1982.  Histamine release by neuromuscular blocking agents in man.. Klin Wochenschr. 60(17):891-5.
Rosow CE, Moss J, Philbin DM, Savarese JJ.  1982.  Histamine release during morphine and fentanyl anesthesia.. Anesthesiology. 56(2):93-6.
Martyn JA, Matteo RS, Greenblatt DJ, Lebowitz PW, Savarese JJ.  1982.  Pharmacokinetics of d-tubocurarine in patients with thermal injury.. Anesth Analg. 61(3):241-6.
Ryan TA.  1982.  Psychology at Cornell after Titchener: Madison Bentley to Robert Macleod, 1928-1948.. J Hist Behav Sci. 18(4):347-69.
1983
Savarese JJ, Ali HH, Basta SJ, Sunder N, Moss J, Gionfriddo MA, Lineberry CG, Wastila WB, el-Sayad HA, Montague D et al..  1983.  The clinical pharmacology of BW A444U. A nondepolarizing ester relaxant of intermediate duration.. Anesthesiology. 58(4):333-41.
Ali HH, Savarese JJ, Basta SJ, Sunder N, Gionfriddo M.  1983.  Evaluation of cumulative properties of three new nondepolarizing neuromuscular blocking drugs BW A444U, atracurium and vecuronium.. Br J Anaesth. 55 Suppl 1:107S-111S.
Basta SJ, Savarese JJ, Ali HH, Moss J, Gionfriddo M.  1983.  Histamine-releasing potencies of atracurium, dimethyl tubocurarine and tubocurarine.. Br J Anaesth. 55 Suppl 1:105S-106S.
1984
Hemmings HC, Williams KR, Konigsberg WH, Greengard P.  1984.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated neuronal phosphoprotein. I. Amino acid sequence around the phosphorylated threonine.. J Biol Chem. 259(23):14486-90.
Hemmings HC, Nairn AC, Greengard P.  1984.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated neuronal phosphoprotein. II. Comparison of the kinetics of phosphorylation of DARPP-32 and phosphatase inhibitor 1.. J Biol Chem. 259(23):14491-7.
Hemmings HC, Nairn AC, Aswad DW, Greengard P.  1984.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. II. Purification and characterization of the phosphoprotein from bovine caudate nucleus.. J Neurosci. 4(1):99-110.
Ouimet CC, Miller PE, Hemmings HC, Walaas SI, Greengard P.  1984.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization.. J Neurosci. 4(1):111-24.
Hemmings HC, Greengard P, Tung HY, Cohen P.  1984.  DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1.. Nature. 310(5977):503-5.
King MM, Huang CY, Chock PB, Nairn AC, Hemmings HC, Chan KF, Greengard P.  1984.  Mammalian brain phosphoproteins as substrates for calcineurin.. J Biol Chem. 259(13):8080-3.